sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com
Summary of Product Characteristics last updated on the eMC: 22/01/2010
SPC Nozinan tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/01/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6.1 - List of Excipients
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   17-Nov-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 2: Rephrased from "Levomepromazine maleate INN (methotrimeprazine maleate BAN) 25mg per   tablet." to "Levomepromazine maleate 25mg per tablet. For excipients, see 6.1."

Section 3: Added detail about tablet: "Circular, grey-white or cream biconvex uncoated tablet. One face with Nozinan around a central 25 and a breakline on the reverse."

Section 5.1: Added the following: " ATC Code: NO5AA02. Pharmacotherapeutic group: Antipsychotics."

Section 6.1 "sodium lauryl sulphate" changed to "Sodium lauryl sulfate"

Date of revision changed to 17/11/09.
Updated on 28/06/2006 and displayed until 22/01/2010
Reasons for adding or updating:
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 04/08/2005 and displayed until 28/06/2006
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 24/03/2004 and displayed until 04/08/2005
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 17/12/2003 and displayed until 24/03/2004
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 20/08/2001 and displayed until 17/12/2003
Reasons for adding or updating:
  • Addition of separate SPCs covering individual presentations

Active Ingredients/Generics

 
   levomepromazine maleate


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk